- Home
- SGLY vs VRAX Comparison
SGLY vs VRAX Comparison
Compare SGLY & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- VRAX
- Stock Information
- Founded
- SGLY 2001
- VRAX 2013
- Country
- SGLY United States
- VRAX United Kingdom
- Employees
- SGLY N/A
- VRAX N/A
- Industry
- SGLY
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SGLY
- VRAX Health Care
- Exchange
- SGLY Nasdaq
- VRAX Nasdaq
- Market Cap
- SGLY 3.4M
- VRAX 2.8M
- IPO Year
- SGLY 2008
- VRAX 2022
- Fundamental
- Price
- SGLY $0.63
- VRAX $0.56
- Analyst Decision
- SGLY
- VRAX Strong Buy
- Analyst Count
- SGLY 0
- VRAX 1
- Target Price
- SGLY N/A
- VRAX $3.00
- AVG Volume (30 Days)
- SGLY 300.3K
- VRAX 246.0K
- Earning Date
- SGLY 11-14-2025
- VRAX 01-01-0001
- Dividend Yield
- SGLY N/A
- VRAX N/A
- EPS Growth
- SGLY N/A
- VRAX N/A
- EPS
- SGLY N/A
- VRAX N/A
- Revenue
- SGLY $1,813,193.00
- VRAX $6,331.00
- Revenue This Year
- SGLY N/A
- VRAX $217,274.83
- Revenue Next Year
- SGLY N/A
- VRAX N/A
- P/E Ratio
- SGLY N/A
- VRAX N/A
- Revenue Growth
- SGLY N/A
- VRAX N/A
- 52 Week Low
- SGLY $0.54
- VRAX $0.52
- 52 Week High
- SGLY $5.49
- VRAX $3.20
- Technical
- Relative Strength Index (RSI)
- SGLY 32.74
- VRAX 35.94
- Support Level
- SGLY $0.71
- VRAX $0.57
- Resistance Level
- SGLY $0.85
- VRAX $0.64
- Average True Range (ATR)
- SGLY 0.05
- VRAX 0.04
- MACD
- SGLY -0.00
- VRAX -0.00
- Stochastic Oscillator
- SGLY 3.45
- VRAX 1.43
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).